ANIP ANI PHARMACEUTICALS INC
Company Analysis
Latest News
ANI Pharmaceuticals Announces ~$560M Recommended Cash Offer to Acquire Egetis Therapeutics AB
ANI Pharmaceuticals (ANIP) announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Egetis Therapeutics AB, a...
ANI Pharmaceuticals' third quarter 2026 revenue of $290.8M beat estimates despite Cortrophin guidance cut
ANI Pharmaceuticals reported strong third quarter results with top and bottom-line beats driven by double-digit growth in its Rare Disease and Generics...
🟢 ANI Pharmaceuticals is trading 5% up in pre-market on Egetis offer valued at approximately $560 million
ANI Pharmaceuticals is trading at $75.49, up +5.36%, after announcing a recommended offer to acquire Egetis Therapeutics for approximately $560 million. - The...
ANI Pharmaceuticals Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
ANI Pharmaceuticals is expected to report Q3 2026 revenue of $280.26 million and adjusted EPS of $2.18, with shares currently trading at $72.23 against a...
ANI Pharmaceuticals Launches Generic Cymbalta in $247 Million Market
ANI Pharmaceuticals launched duloxetine delayed-release capsules, a generic version of Cymbalta®. The product will be available in 20 mg, 30 mg, and 60 mg...
🟢 ANI Pharmaceuticals is trading 5% up in pre-market
ANI Pharmaceuticals is trading at $76.04, up 5.34% versus the October 2 close; no fresh October 5 catalyst was identified. - The latest company announcement...
ANI Pharmaceuticals Eyes 48% Upside After Leerink Sets $104 Price Target
Leerink Partners initiated coverage on ANI Pharmaceuticals (NASDAQ:ANIP) on Wednesday with an outperform rating. The firm set a price target of $104.00 for...
ANI Pharmaceuticals eyes profit boost, driven by new tariffs on imported generics
An August 3, 2026, analysis identifies ANI Pharmaceuticals as a primary beneficiary of new tariffs on Canadian imports and increased taxes on generic drugs....
🔴 ANI Pharmaceuticals is trading 5.59% down today after reduced Cortrophin Gel revenue guidance
ANI Pharmaceuticals is trading 5.59% down at $78.02 after investors focused on reduced Cortrophin Gel revenue guidance. • Q2 revenue reached $266 million, and...
ANI Pharmaceuticals beats second quarter 2026 expectations but trims full-year Cortrophin revenue guidance
ANI Pharmaceuticals reported a robust second quarter 2026, with revenue and adjusted earnings exceeding analyst estimates. Growth was primarily fueled by a...
🔴 ANI Pharmaceuticals is trading 6.81% down in pre-market ahead of August 7 earnings
ANI Pharmaceuticals is trading 6.81% down at $77.00 in pre-market after no confirmed company-specific overnight catalyst was identified. - Second-quarter 2026...
ANI Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 07, 2026
ANI Pharmaceuticals is expected to report Q2 2026 revenue of $260.13 million and adjusted EPS of $2.04, with the stock trading at approximately $80.06,...
ANI Pharmaceuticals Appeals Court Ruling, Seeking 5% Royalty on Cancer Therapy
ANI Pharmaceuticals will appeal a Delaware trial court decision in its ongoing legal dispute with CG Oncology. The court recently denied ANI’s post-trial...